ROCHESTER, Minn. (KTTC) – A Winona industrial supply company provided assistance to a Wisconsin high school student’s science ...

Lynozyfic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.

Regeneron Pharmaceuticals, Inc. faces challenges with Eylea sales but sees growth from Dupixent and obesity drugs. Click for ...

Regeneron shows financial strength and fair valuation, but trevogrumab's Phase 2 progress adds uncertainty. Click here to ...

Slashing adverse drug reactions through pharmacogenetics and advanced AI could help rehabilitate the pharmaceutical ...

Previous reports (including ours) said that a company named Regeneron was supposed to be the buyer, but that deal ended up ...

CHENNAI: Biocon Biologics, the biosimilars subsidiary of Biocon Ltd, said on Friday that Health Canada has granted a Notice ...

Anne Wojcicki's TTAM Research Institute has received court approval to acquire 23andMe, the genetic testing company she ...

In January of 2024, the class action lawsuit was filed against the company, alleging that 23andMe failed to protect the data ...

A bankruptcy judge approved the sale of 23andMe's assets and business operations to a nonprofit led by 23andMe’s co-founder ...

Provided by PR Newswire Jun 26, 2025, 12:00:00 PM Ultima Genomics Selected to Support the World's Largest Proteomics Studies to Date Led by Regeneron Genetics Center ...

In this video, Robert J. Smith, MD, discusses the many treatment options available to patients with atopic dermatitis.